Choosing the best treatment approach to dyslipidemia: monotherapy vs combination therapy
CHANNEL
Topic: Lipids: Drug therapy
Session type: Industry Q&A session
Date: Time:* -

See more details
Watch Replay
Subtitle
Sponsored by SERVIER
Learning objectives
Dyslipidemia is one of the most important risk factors of cardiovascular diseases Recent guidelines recommend a more frequent use of a statin/ezetimibe combination in a SPC to optimize the management and thus the prognosis
Presentations
ESC Guidelines 2019: what has changed?
Speaker: Alberto Zambon (Padua, Italy)
Time:

What is the key evidence supporting LDL-C control at lower targets, with earlier intervention for better outcomes in the long-term?
Speaker: Leopoldo Perez De Isla (Madrid, Spain)
Time:

Broader usage of combinations in daily clinical practice: what benefits for patients?
Speaker: Alberto Zambon (Padua, Italy)
Time:

How have the French and Spanish (local) Cardiology Societies interpreted the ESC Guidelines? Insights and recommendations.
Speaker: Leopoldo Perez De Isla (Madrid, Spain)
Time:

Statin/ezetimibe combinations: data and evidence, for which patients.
Speaker: Alberto Zambon (Padua, Italy)
Time:

Feedback on patients treated with high intensity statin/ezetimibe combinations. Do we need to go further?
Speaker: Alberto Zambon (Padua, Italy)
Time:

Feedback on patients treated with high intensity statin/ezetimibe combinations. Do we need to go further?
Speaker: Leopoldo Perez De Isla (Madrid, Spain)
Time: